Skip to main content

Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer - ScienceDirect

Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer - ScienceDirect

sciencedirect.com

Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

3 minutes
Elsevier logo

Outline

  1. ABSTRACT
  2. Keywords
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. CONCLUSIONS
  8. REFERENCES
  9. Appendix. Supplementary materials

Figures (4)

  1. Figure 1. Treatment Plan

  2. Figure 2. Consort Diagram

  3. Figure 3. Swimmer plot

  4. Figure 4. Kaplan Meier Plots of Estimated Survival

ABSTRACT

Purpose: Oligorecurrent prostate cancer limited to the pelvic lymph nodes (LNs) can be treated with whole pelvis radiotherapy. Radiotherapy may also be beneficial for oligorecurrent prostate cancer in the para-aortic (PA) LNs.

Methods: We identified a sequential cohort of patients with oligorecurrent prostate cancer to the PA LNs (≤5) treated with elective, conventionally fractionated PA radiotherapy (PA-RT) plus simultaneous integrated boost (SIB) to LN+ disease at our institution from 2015 to 2021. The primary endpoint was progression-free survival (PFS) at 2 years using Kaplan-Meier estimation. PFS was defined as the time from PA-RT to the first event: biochemical failure (PSA 50% above post-treatment nadir and at least 4 ng/mL), escalation of therapy, radiological progression, or death. Secondary endpoints included 2-year biochemical failure-free survival (BFFS), 2-year overall survival (OS) and treatment-related toxicity.

Results: Thirty-four patients were included (median age 66 years), and 82.4% were status post-prostatectomy. The median time from diagnosis to PA-RT was 5.7 years. The median PSA at PA-RT was 3.15 ng/mL (IQR 1.30-5.90). All patients were treated to the PA region with 45-50 Gy in 25 daily fractions. LN+ disease received a SIB to a median dose of 62.5 Gy (range 60-65 Gy). Most received photon-based RT, while 21.1% were treated with proton therapy. Nearly all (97.1%) patients had androgen deprivation therapy (ADT) and 52.9% abiraterone. The median follow-up time from PA-RT was 21.5 months. PFS at 2-years was 83.4% (95% CI: 68.6-100%). Two-year BFFS was 90.4% and OS 100%. There were no grade 3 or higher acute toxicities.

There were 10 (29.4%) grade 2 acute toxicities. There were two (5.9%) grade 3 chronic toxicities and 4 (11.8%) chronic grade 2 toxicities.

Conclusion: PA-RT for oligorecurrent prostate cancer has low toxicity with very encouraging early disease control. These preliminary results require validation in prospective studies.

Keywords

prostate cancer

radiation therapy

oligorecurrent

oligometastases

salvage

Cited by (0)

View full text

© 2022 Elsevier Inc. All rights reserved.

 

Comments

Post a Comment

Popular posts from this blog

Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey | Prostate Cancer and Prostatic Diseases

Image
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey | Prostate Cancer and Prostatic Diseases Review Article Open access Published: 17 October 2024 Hannah D. McManus ,  Tanya Dorff , Alicia K. Morgans , Oliver Sartor , Neal Shore &  Andrew J. Armstrong   Prostate Cancer and Prostatic Diseases ( 2024 ) McManus, H.D., Dorff, T., Morgans, A.K. et al. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis (2024). https://doi.org/10.1038/s41391-024-00906-z   47 Accesses ...
Read more

Actinium-225 Theranostics for Advanced Prostate Cancer:

Image
 A Patient's Guide to the State of the Science An IPCSG patient-education feature — April 2026 BLUF (Bottom Line Up Front):   Actinium-225 (Ac-225) PSMA-targeted alpha therapy is producing some of the most striking PSA response numbers ever seen in heavily pretreated mCRPC — about 65% of men achieve a PSA50 response across pooled studies, a figure that exceeds what beta-emitting Lu-177 PSMA delivers in the same setting. It is showing meaningful activity even in men who have already progressed through Pluvicto (Lu-177 PSMA-617). However, Ac-225 PSMA therapy is not a finished product: it remains investigational only — no Ac-225 drug has FDA approval for prostate cancer as of April 2026 — and the dominant problem is severe, often permanent, dry mouth (xerostomia) from off-target damage to the salivary glands, which is reported in roughly 80–85% of treated patients. A wave of randomized phase 2/3 trials (PSMAcTION, CONVERGE-01, AcTION, TATCIST, ACCEL, AlphaBreak...
Read more

The Other Patient: Care for the Caregivers

Image
Informed Prostate Cancer Support Group (IPCSG) Newsletter  |  April 2026 What Our Partners and Caregivers Carry on This Roller Coaster A close look at the hidden burden borne by spouses and care partners across surgery, ADT, radiation, imaging, and theranostics   Prepared for the IPCSG Community  |  April 2026 Bottom Line Up Front (BLUF) When a man is diagnosed with prostate cancer and embarks on treatment — whether surgery, radiation, androgen deprivation therapy (ADT), PSMA imaging, or the newest theranostics — his spouse or care partner shoulders a second, often invisible, patient journey alongside him. Research consistently shows that partners experience rates of anxiety and depression equal to or greater than patients, sacrifice thousands of hours of work and personal time, suffer significant sexual and intimacy losses, and receive far less clinical attention th...
Read more